Paclitaxel - MGI GP
Alternative Names: Paclimer microspheresLatest Information Update: 15 Jan 2022
At a glance
- Originator MGI GP
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP Inc
- 30 Jun 2002 Paclimer® Microspheres technology is available for licensing (http://gulifordpharm.com)
- 30 Jun 2002 Discontinued - Phase-I/II for Non-small cell lung cancer in USA (unspecified route)